Rep. Gilbert Ray Cisneros, Jr. Buys Boston Scientific Corporation (NYSE:BSX) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Boston Scientific stock on May 19th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.

Boston Scientific Stock Down 1.1%

Shares of BSX traded down $0.54 on Wednesday, reaching $48.42. The company’s stock had a trading volume of 22,656,177 shares, compared to its average volume of 17,713,734. Boston Scientific Corporation has a twelve month low of $47.17 and a twelve month high of $109.50. The stock has a market capitalization of $71.98 billion, a PE ratio of 20.26, a PEG ratio of 0.91 and a beta of 0.56. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The firm has a fifty day moving average of $57.28 and a 200-day moving average of $75.83.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its board has approved a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Institutional Investors Weigh In On Boston Scientific

Several large investors have recently modified their holdings of the stock. Claret Asset Management Corp grew its holdings in Boston Scientific by 4.4% during the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after purchasing an additional 102 shares during the period. Cary Street Partners Investment Advisory LLC lifted its position in shares of Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after buying an additional 103 shares during the last quarter. Outfitters Financial LLC grew its stake in shares of Boston Scientific by 0.5% during the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after acquiring an additional 110 shares during the period. Fayez Sarofim & Co raised its stake in Boston Scientific by 2.1% in the 3rd quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock valued at $520,000 after acquiring an additional 111 shares during the period. Finally, Natural Investments LLC lifted its holdings in Boston Scientific by 2.9% during the fourth quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock valued at $384,000 after purchasing an additional 112 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on BSX. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday, May 28th. Stifel Nicolaus set a $75.00 price objective on shares of Boston Scientific in a report on Wednesday, May 27th. Barclays reduced their target price on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research note on Thursday, May 28th. Truist Financial dropped their price target on shares of Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday, June 4th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Boston Scientific in a report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $85.92.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig bought 3,580 shares of the stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $56.68 per share, with a total value of $202,914.40. Following the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David C. Habiger purchased 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 9,800 shares of company stock valued at $554,012 over the last quarter. Company insiders own 0.34% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.